BPC-157 vs TB-500: how does the research compare?
Both compounds are reviewed against the same standard: what has been studied, in whom, and what the studies reported. Human evidence and preclinical evidence are kept separate throughout.
Research education only — not medical advice
BPC-157
Synthetic gastric juice-derived peptide sequence
- Human research
- Very limited
- Preclinical research
- Strong
Preclinical — human research has not followed the animal literature.
Full research profileTB-500
Fragment of thymosin beta-4
- Human research
- Very limited
- Preclinical research
- Moderate
Preclinical.
In the compound indexThe Wize summary
- What each is
BPC-157
Synthetic gastric juice-derived peptide sequence
TB-500
Fragment of thymosin beta-4
- Human evidence
BPC-157
very limited
TB-500
very limited
- Preclinical evidence
BPC-157
strong
TB-500
moderate
- What remains unknown
BPC-157
Preclinical — human research has not followed the animal literature.
TB-500
Preclinical.
Bottom line
Human research for BPC-157 is rated very limited, and for TB-500 it is rated very limited. That rating describes how much human research exists — not whether either compound works, and not whether either is safe.
How these two relate.
Both are preclinical tissue-repair peptides commonly discussed together. No human combination data exists; evidence is animal-level.
Detail by dimension.
Compound class
- BPC-157
- Synthetic gastric juice-derived peptide sequence
- TB-500
- Fragment of thymosin beta-4
Mechanism being investigated
- BPC-157
- A stable pentadecapeptide sequence originally derived from human gastric juice protein. Its mechanism is not fully established; preclinical studies report effects on angiogenesis, fibroblast activity, and tissue repair.
- TB-500
- A synthetic fragment of thymosin β-4, a protein involved in actin binding and cell migration. Studied preclinically for wound healing, angiogenesis, and tissue repair.
Receptor targets
- BPC-157
- Not established (research areas: angiogenesis and fibroblast pathways)
- TB-500
- Not established (actin-regulation / cell migration pathways)
Research areas
- BPC-157
- Recovery, Gut research, Inflammation
- TB-500
- Recovery, Inflammation, Muscle research
Half-life, as reported
- BPC-157
- Not established in humans; animal pharmacokinetic data suggest a very short half-life
- TB-500
- Not firmly established; preclinical data only
Human research
- BPC-157
- Very limited — No published randomized human trials located; evidence is overwhelmingly preclinical.
- TB-500
- Very limited — No published randomized human trials located for this fragment specifically.
Preclinical research
- BPC-157
- Strong — An extensive preclinical literature reports effects on tendon, ligament, and GI healing in animal models.
- TB-500
- Moderate — Preclinical studies (largely thymosin β-4 based) report effects on tissue repair and cell migration.
Mechanistic research
- BPC-157
- Moderate — Proposed mechanisms (angiogenesis, growth factor expression) are supported by animal data but unconfirmed in humans.
- TB-500
- Limited — Actin sequestration and cell-migration effects are characterized at the protein level; whole-organism translation is unclear.
What studies reported
- BPC-157
- Extensive animal literature reports improved healing of tendons, ligaments, and GI lesions; human data are minimal.
- TB-500
- Preclinical models report improved tissue repair and cell migration; human data are minimal.
Reported adverse effects in studies
- BPC-157
- No systematic human safety data exist; preclinical studies report few observable effects at studied doses.
- TB-500
- No systematic human safety data exist.
Research maturity
- BPC-157
- Preclinical — human research has not followed the animal literature.
- TB-500
- Preclinical.
Study records.
Published research already verified into the Wize study library. Each record carries its own design, findings, and limitations.
BPC-157
No verified study record for BPC-157 is in the Wize library yet. Records are added only once the publication has been checked against its source.
TB-500
No verified study record for TB-500 is in the Wize library yet. Records are added only once the publication has been checked against its source.
Sources & research.
These are search and registry entry points, not endorsements. Every finding above should be checked against the primary publication before it is relied on.
What this comparison cannot settle.
A comparison of research is not a comparison of treatments. Where a study has directly compared BPC-157 with TB-500, it appears above with a link to its record; where none appears, we have not identified one. Neither compound's evidence base can say which is more appropriate for any person, at any dose, or in any situation — and the letter on each card measures how much human research exists, not how well anything works.
Continue researching.
Get a new guide every week.
Subscribe free and the Beginner's Guide, the COA Guide, and the Safety Guide are yours the moment you sign up.